uniQure Prices $225 Million Upsized Offering of 4.95 Million Shares
QURE•uniQure priced an upsized offering of 4,945,055 ordinary shares at $45.50 each, raising approximately $225 million in gross proceeds. Underwriters received a 30-day option to buy up to 741,758 additional shares, with closing expected around June 25, 2026, subject to customary conditions.
1. Offering Terms
uniQure launched an upsized underwritten public offering of 4,945,055 ordinary shares at $45.50 per share, anticipated to generate about $225 million in gross proceeds before underwriting discounts, commissions and offering expenses.
2. Underwriter Option and Closing Timeline
The company granted underwriters a 30-day option to purchase up to 741,758 additional shares at the public offering price less discounts and commissions. The offering is slated to close on or about June 25, 2026, pending customary conditions.
3. Pipeline and Corporate Background
As a leading gene therapy company, uniQure holds approval for its hemophilia B treatment and is advancing proprietary therapies for Huntington’s disease, refractory temporal lobe epilepsy, Fabry disease and other severe conditions.
